Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes [Original Articles]

Conclusions—
Genotype-dependent effects on C-reactive protein and cholesterol efflux are supportive of dalcetrapib benefits on atherosclerotic cardiovascular outcomes in patients with the AA genotype at polymorphism rs1967309.

Clinical Trials Registration—
ClinicalTrials.gov; Unique Identifiers: NCT00658515 and NCT01059682.

Source: Circulation: Cardiovascular Genetics - August 15, 2016 Category: Cardiology Authors: Tardif, J.-C., Rhainds, D., Brodeur, M., Feroz Zada, Y., Fouodjio, R., Provost, S., Boule, M., Alem, S., Gregoire, J. C., LAllier, P. L., Ibrahim, R., Guertin, M.-C., Mongrain, I., Olsson, A. G., Schwartz, G. G., Rheaume, E., Dube, M.-P. Tags: Clinical Studies, Inflammation, Lipids and Cholesterol, Pharmacology, Coronary Artery Disease Original Articles Source Type: research